TB is a top priority for R&D

The Hague – KNCV Tuberculosis Foundation today shares in the outrage expressed by our partners in the TB community regarding the exclusion of  tuberculosis from the recently published WHO list of antibiotic-resistant “priority pathogens”. On February 28th, the WHO responded by stating that “addressing drug-resistant TB research is a top priority for WHO and for the world” given the “global consensus that new TB treatments are already a top priority for R&D”. KNCV welcomes this needed clarification and looks forward to accelerated action following the Global Ministerial Conference on TB in Moscow in November of this year. It is KNCV’s conviction that this event, and other platforms for collaboration and effective partnerships, will have a significant impact in ending the global TB epidemic. Therefore, let us take immediate action to demand further investment in development of novel drugs to treat drug resistant TB and halting the needless suffering incurred by communities, families and patients.

KNCV has been fighting TB since its establishment in 1903. Over the past 120 years, the organization has acquired indispensable knowledge and experience in the field of effective TB prevention and care, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework and integrity
Our patroness
Partner with us


De versie van de browser die je gebruikt is verouderd en wordt niet ondersteund.
Upgrade je browser om de website optimaal te gebruiken.